Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: Mature results of the G4 trial

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 1044-1048

  Advani, R H ^a   Hoppe, R T ^a   Baer, D ^b   Mason, J ^b   Warnke, R ^a   Allen, J ^a   Daadi, S ^a   Rosenberg, S A ^a   Horning, S J ^a  

^a STANFORD UNIVERSITY   (United States)

^b Northern California Kaiser Permanente ^*  (United States)

Author keywords

Abbreviated Stanford V regimen; Early stage Hodgkin lymphoma; Involved field radiotherapy

Indexed keywords

BLEOMYCIN; CHLORMETHINE; COTRIMOXAZOLE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; RANITIDINE; VINBLASTINE; VINCRISTINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSTIPATION; DISEASE SPECIFIC SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; WEAKNESS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 84875595072     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds542     Document Type: Article

References (18)

1. Herbst C, Rehan FA, Brillant C et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 2009; 95: 494-500.
2. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-1927.
3. Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-4206.
4. Ferme C, Divine M, Vranovsky A et al. Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. Blood (ASH Annual Meeting Abstracts) 2005; 106: 813.
5. Engert A, Plutschow A, Eich HT et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-652.
6. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
7. Horning SJ, Hoppe RT, Mason J et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15: 1736-1744.
8. Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
9. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203-223.
10. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185-198.
11. Meyer RM, Gospodarowicz MK, Connors JM et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N Engl J Med 2012; 366: 399-408.
12. von Tresckow B, Plutschow A, Fuchs M et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 2012; 30: 907-13.
13. Noordijk EM, Thomas J, Ferme C et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). ASCO Meeting Abstracts 2005; 23: 6505.
14. Advani R, Horning SJ, Jonathan E et al. Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: preliminary results of the Stanford G5 Study. ASCO Annual Meeting Abstracts 2011; 29: 8064.
15. De Bruin ML, Sparidans J, van't Veer MB et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009; 27: 4239-4246.
16. Gallamini A, Patti C, Viviani S et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-560.
17. Radford J, O'Doherty M, Barrington S et al. Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma with a 'negative' FDG-PET scan after 3 cycles ABVD. Blood (ASH Annual Meeting Abstract) 2008; 112369.
18. Eastern Cooperative Oncology Group. Chemotherapy based on PET scan in treating patients with stage I or stage II Hodgkin lymphoma. ClinicalTrials.gov Bethesda (MD), National Library of Medicine (US), 2012 (http://clinicaltrials.gov/ct2/show/NCT01390584).